contraindications for glp-1 agonists What are the starting Glucagon-like peptide-1 (GLP-1) receptor agonists? Exploring the Side Effects of

Tirzepatide, a newer GLP-1/GIP dual agonist, and retatrutide, a triple agonist still in trials, have pushed results even further, with average weight loss approaching 2025% of body weight

Mortality rate was significantly lower in the GLP-1RAs group (HR 0.62

Are you stable right now, or still titrating

How GLP-1/GIP dual agonists work for weight loss GLP-1/GIP dual agonists (or "co-agonists") mimic the actions of two peptide hormones, GLP-1 and GIP

[DOI] [PubMed] [Google Scholar] 711.Kohno D., Sone H., Tanaka S., Kurita H., Gantulga D., Yada T

A large study that compared tirzepatide to semaglutide showed that in non-diabetic, overweight adults, the risk of gastroparesis was much higher in semaglutide recipients compared to tirzepatide